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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder, and the majority of ALS are sporadic (SALS).
Recently, several causative genes for familial ALS (FALS) were identiﬁed, but the cause of the SALS is still unknown. This time, we
aimed to identify the genetic background of SALS. First, we applied the new sensitive screening methods: high-resolution melting
(HRM) analysis. HRM analysis detected 18 out of 19 known SOD1 gene mutations (94.7% sensitivity). Next, we screened SOD1,
threenovel mutations(C6Y,Q22H,andS134T)wereidentiﬁed inourown184SALScases(1.63%prevalence),andfourmutations
in another 255 SALS cases (1.56% prevalence) registered from all over Japan. The patients with SOD1 mutations suggested a
relatively young onset and limb involvement at onset. The HRM analysis is a sensitive and easy screening method; we will use this
method for screening other ALS causative genes and revealing the genetic background of SALS.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder primarily aﬀecting motor neurons in the spinal
cord, brain stem, and cerebral cortex. Five to ten percent of
ALS cases are familial; the others are believed to be sporadic
[1]. Mutations in the Cu/Zn superoxide dismutase gene
(SOD1;OMIM 147450)are themost frequentgeneticdefects
known to underlie ALS, accounting for 20% of familial cases
(FALS)and oneto sevenpercent of apparently sporadic cases
(SALS) [1–7]. Recently, other mutations like the TARDBP
gene (TDP-43) [8, 9], ANG gene [10], FUS/TLS gene [11],
and OPTN gene [12] were identiﬁed as causative of ALS.
Despite this genetic heterogeneity, SOD1 mutations are the
most frequent cause of adult onset ALS. Here, we report the
results of screening for SOD1 mutations in the 184 SALS
cases in our hospital and 265 ALS cases all over Japan by
high-resolution melting (HRM) analysis.
HRM analysis is a mutation scanning technique that
monitors the progressive change in ﬂuorescence caused by
the release of an intercalating DNA dye from a DNA duplex
as it is denatured with marginal increases in temperature
[13]. The shifts and shapes of melting curves, there are
obtained as ﬂuorescence diﬀerence plots, are used to dis-
tinguish between mutations and controls. HRM analysis
of PCR products ampliﬁed in the presence of LC Green
Plus can detect all heterozygous and most homozygous
sequence variations through diﬀerences in shape and posi-
tion of a melting curve compared with a wild-type melting
proﬁle.Althoughsingle-strand conformationpolymorphism
(SSCP) [2, 3, 14–20] and denaturing high-performance
liquid chromatography (DHPLC) [5, 6] seem to be the main
screening strategies for SOD1 mutations, HRM analysis has
i t so w na d v a n t a g e s .T h i si st h eﬁ r s tr e p o r to fH R Ma n a l y s i s
being applied to the SOD1 screening. In this paper, we
report the high sensitivity of HRM analysis for known SOD12 Neurology Research International
Table 1: Reported SOD1 mutations to determine the sensitivity of
HRM analysis.
Exon1 A4V, L8V, V14G
Exon2 H43R
Exon3 D76Y
Exon4 N86S, A89V, D90A (hetero), G93S, D101G, S105L,
G114A, R115G
Exon5 L126delTT, G127X, A140A, L144F type2, L144FVX
Underlined mutation could not detect the mutationby HRM analysis.
mutations, and the prevalence and clinical features of SOD1
mutations in Japanese SALS cases.
2.PatientsandMethods
2.1. Patient Group 1. A total of consecutive 184 SALS cases
(109 males and 75 females) visited our Neurology Division
at the Jichi Medical University Hospital in Tochigi, Japan.
Ethical approval was granted by the Bioethics Committee
for Human Gene Analysis of our university and informed
consent was obtained from all subjects according to the
Declaration of Helsinki. Every patient fulﬁlled the diagnostic
criteria for ALS as outlined by the El Escorial Revisited [21]
classiﬁcation; 177 deﬁnite, probable or possible ALS and 7
suspected ALS. None of the cases had a family history of a
neuromuscular disorder. There was no signiﬁcant diﬀerence
in onset age between 109 males and 75 females (males: 60.4
years on average with a range of 27–80; females: 64.3 years
with a range of 34–83).
2.2. Patient Group 2. In 2006, the Japanese Consortium
for Amyotrophic Lateral Sclerosis Research (JaCALS) was
organized with the aim of investigating the relationships
of clinical and genetic aspects of ALS in Japan. The Ethics
Committee of each institution granted ethical approval.
The inclusion criteria for registration with the JaCALS
are: (1) adult onset, steady progressive course, (2) deﬁnite,
probable or possible ALS based on the El Escorial Revisited
[21] criteria for diagnosis of ALS, and (3) informed consent
for the genetic study and clinical checking every three
months. From 2006 to 2008, 265 patients (10 FALS and 255
SALS) were registered, and blood samples and clinical data
having been obtained by neurologists.
2.3. Reported SOD1 Mutations. We used 19 reported SOD1
mutations in all ﬁve exons (Table 1) to determine the
sensitivity of the HRM analysis. 19 reported SOD1 muta-
tions were obtained from our collaborators, Dr. Andersen
P. (Ume˚ a University, Sweden) and Dr. Watanabe Y. (Tottori
University, Japan), and they were already direct sequenced
and conﬁrmed they had the mutations.
2.4. HRM Analysis and Sequencing. Genomic DNA was
extracted from lymphocytes using a standard procedure. We
designed PCR primers for HRM analysis to screen all ﬁve
exons in SOD1. DNA samples were ampliﬁed with double-
stranded DNA-binding dye LC Green Plus (Idaho Technol-
ogy). PCR was performed with a Veriti 96-Well Thermal
Cycler (Applied Biosystems) in 10µL reaction mixtures
comprising 10ng DNA, 1XPCR buﬀer, LC Green Plus
(Idaho Technology), and 1U Taq polymerase, with 0.25µM
each forward and reverse primers. Initial denaturation was
performed at 95◦C for 2min, followed by 45 cycles of 94◦C
for 30sec and 62–68◦C for 30sec, with a ﬁnal cycle of 94◦C
for 30sec and 25◦Cf o r3 0s e c .
We performed melting acquisition with a 96-well Light
Scanner (Idaho Technology). The plate was heated from 80
to 98◦Ca t0 . 1 ◦C/sec with a 300ms frame interval, 15ms
exposure, and 100% LED power. Light Scanner Software was
used for melting curve analysis. The Light Scanner analyses
of 96 samples were performed in around 10min. Sequencing
of samples indicated to include mutations was then carried
out using a BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems) and an ABI 310 automated sequencer
(PE Applied Biosystems).
First we examined 19 reported SOD1 mutations to deter-
mine the sensitivity of HRM analysis. Next, we applied this
method to Japanese ALS patients for mutation screening of
SOD1.
3.Results
3.1. Sensitivity of HRM Analysis. HRM analysis clearly
distinguished 18 of 19 previously identiﬁed SOD1 mutations
from normal controls. The mutation detection sensitivity
was 94.7% for the reported mutations. The melting curves
of control samples (wild-type) were tightly grouped for all
fragments,andaltereddiﬀerencecurveswereeasilyidentiﬁed
for the 18 mutations(Figure 1). The mutation that could not
be detected was Gly 114 Ala.
3.2. SOD1 Mutations and the Clinical Characteristics in
Group 1. We found SOD1 mutations in three out of the 184
SALS cases (1.63%) in the group 1. The mutations identiﬁed
were all novel: Cys 6 Tyr (C6Y) and Gln 22 His (Q22H) in
exon 1, and Ser 134 Thr (S134T) in exon 5 (Figure 2).
In case 1, a 34-year-old woman, there was a single-base
pair substitution in exon 1 at codon 6 (TGC to TAC). This
change created a cysteine 6 to tyrosine missense mutation
(C6Y). She awoke with painful cramping and weakness in
the right leg almost every morning at the age of 33 years.
The cramping resolved, but her right leg weakness pro-
gressed and become accompanied by fasciculation. One year
after the onset, neurological examination showed marked
muscle atrophy and prominent fasciculation in her right
leg. Tendon reﬂexes were normal, and plantar responses
were ﬂexor. Sensations in all four modalities were intact.
Nerve conduction studies revealed mild reduction of motor
nerve conductionvelocity without conductionblock.Needle
electromyographic analysis showed repetitive discharges and
hyperexcitability only in the right leg. Extensive screening
f o rc a u s e so ft h em o t o rn e u r o p a t h yw a sn e g a t i v e .T h e
muscle weakness and atrophy progressed, and spread to the
other parts of her body despite treatment with intravenousNeurology Research International 3
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Figure 1: Melting curves andsubtractive ﬂuorescent diﬀerence plots of a wild type (gray lines)and reported SOD1 mutations(colourlines).
Diﬀerence plots were easily identiﬁed for the mutations.
gamma globulin, cyclophosphamide, and plasmapheresis.
The disease course was rapid and the bulbar symptom
developed in the last stage. She expired 3 years after disease
onset.
In case 2, a 48-year-old man, there was a single-base
pair substitution in exon 1 at codon 22 (CAG to CAC).
This change created a glutamine 22 to histidine missense
mutation (Q22H). He developed left leg weakness and
atrophy at the age of 46 years. Two years after the onset,
neurological examination showed muscle weakness, atrophy
and fasciculation were observed in the left leg. Tendon
reﬂexes were brisk in the right leg and both arms. The
weakness and atrophy spread to the right leg, conﬁning him
to a wheelchair at 51 years old and to bed at 52 years old. He
underwent tracheotomy because of progressive respiratory
failure, and artiﬁcial ventilation support was started eight
years after disease onset. Five years after artiﬁcial ventilation
support was started, he moved to another hospital and thus
we could not follow him further.
In case 3, a 69-year-old man, there was a single-base pair
substitution in exon 5 at codon 134 (AGT to ACT). This
change created a serine 134 to threonine missense mutation
(S134T).Henoticedgaitdisturbanceduetomuscleweakness
o ft h el o w e rl i m b sa tt h ea g eo f6 2y e a r s .T h ew e a k n e s s
progressively worsened, and he could not walk by himself
at 67 years old. Neurological examination showed muscle
weakness, and fasciculation were evident in the upper and
lower limbs. Tendon reﬂexes were diminished and plantar
responses were ﬂexor. No sensory abnormalities were noted.
Nerve conduction studies demonstrated normal motor
and sensory nerve conduction velocities. Electromyographic
analysis revealed fasciculation and denervation in the upper
and lower limbs. Although upper motor neuron impairment
w a sn o tc o n ﬁ r m e d ,A L Sw a sc o n s i d e r e da st h em o s tp r o b a b l e4 Neurology Research International
0
0.05
0.1
0.15
−0.5
D
i
ﬀ
e
r
e
n
c
e
c
u
r
v
e
s
0
0.2
0.4
0.6
0.8
1
88 89 90 91 92 93 94
T
e
m
p
e
r
a
t
u
r
e
s
h
i
f
t
e
d
c
u
r
v
e
s
88 89 90 91 92 93 94
CAG  CAC GTA CAC GGCC
 G G C C GTG  TAC GTG  CTG
T G C
Ala Val Val Leu Tyr
Cys
5 
5 
3 
3 
Temperature ◦C Temperature ◦C
(a) Case 1 (20 G > A; C6Y)
TTC GAG   CAC AAGG
CAG
Phe Glu His Lys
Gln
88 89 90 91 92 93
0
0.2
0.4
0.6
0.8
1
T
e
m
p
e
r
a
t
u
r
e
s
h
i
f
t
e
d
c
u
r
v
e
s
−0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
−0.04
−0.06
Di
ff
er
enc
e
cur
v
e
s
87 88 89 90 91 92 93 87 94 94
Temperature ◦C Temperature ◦C
(b) Case 2 (69 G > C; Q22H)
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Figure 2: Sequence (upper), melting curves (left lower) and subtractive ﬂuorescent diﬀerence plots (right lower) of the three novel
mutations.
diagnosis. The weakness progressed very slowly, and he died
of respiratory insuﬃciency seven years after disease onset.
3.3. SOD1 Mutationsin Group2. We found SOD1 mutations
in eight out of 265 cases. Of these, four had family histories,
mutations being Leu 38 Val (L38V) and His 46 Arg (H46R)
in exon 2, Gly 93 Ser (G93S) in exon 3 and Gly 141 Ala
(G141A) in exon 5. The G141A found in a woman whose
brother probably died of ALS was a novel mutation. In this
case,left hand weakness occurred at 57years old.The clinical
course was rapid that she died at 3 years and 11 months
after the onset. The remaining four SOD1 mutations were
found in sporadic cases, mutations being Lys 3 Glu (K3E) in
exon 1 and Gly 93 Ser (G93S) in exon 3. K3E was a novel
mutation found in a woman who noticed right leg weakness
at52yearsold,andartiﬁcial ventilationsupportwasstarted 6
years after the onset. The G93S mutation was found in three
unrelated patients. The prevalence of SOD1 mutations in the
SALS cases was 1.56% (4 of 255 SALS cases) in the group 2.
4.Discussion
4.1. HRM Analysis on SOD1. This is the ﬁrst report of
HRM analysis for SOD1 mutation screening. HRM analysis
could clearly distinguish 18 of 19 reported SOD1 mutations
from normal controls. We have demonstrated that HRM
analysis is a rapid and sensitive (94.7% sensitivity) method
for mutation scanning of SOD1. SSCP is a method that
most laboratories use for the screening of gene mutations,
but the sensitivity is not high (80% to 90%) [7]. DHPLC
using WAVE system is also a screening method, but it
cannot detect the D90A mutation [6], which is one of
the worldwide detected SOD1 mutations, and the most
appropriate condition for analysis is diﬃcult to determine.
Using HRM analysis, we can analyze within 5 to 10 minutes
on 96 samples and the running cost is not expensive.
The one mutation that HRM analysis could not detect
was guanine to cytosine at nucleotide 341 substituting
glycine (GGC) to alanine (GCC) at codon 114. On the other
hand, guanine (TTG) to cytosine (TTC) mutations (L144F),
and alanine (GCT) to alanine (GCA) mutations (A140A) in
othersamples were detected with thismethod, indicating the
possibility that the G to C mutation detection failure may be
a sequence-speciﬁc phenomenon.
4.2. SOD1 Mutations in SALS. We applied this method to
our own 184 (group 1) and 255 (group 2) Japanese cases
of SALS, ﬁnding three diﬀerent novel SOD1 mutations in
three cases in the former (mutation prevalence, 1.63%), and
one novel and three known mutations in four cases in the
latter(mutationprevalence,1.57%).We listed the prevalence
and identiﬁed mutations of SOD1 in SALS cases in other6 Neurology Research International
Table 2: SOD1 mutations in SALS patients of the diﬀerent countries.
Country Total SALS No. of SOD1 SOD1/Total Mutations identiﬁed Screening method Author, year
North England 46 1 2.1 D101N SSCP Jones et al. 1994 [14]
Scotland 57 4 7.0 E21K, I113T SSCP Jones et al. 1995 [2, 15]
Scandinavia 355 14 3.9 V14G, D90A (hetero & homo) SSCP Andersen et al. 1997 [16]
England 155 4 2.6 D90A, I113T, V118KTGPX SSCP Jacksonet al. 1997 [17]
England 175 5 2.8 G72S SSCP Shaw et al. 1998 [18]
Belgium 69 3 4.3 D90A, N139N, IVS + 19A > G SSCP Aguirre et al. 1999 [3]
Italy 48 3 6.3 D90A (homo),I113T, A95T DS Gellera et al. 2001 [22]
Spain 87 1 1.2 N65S SSCP Garc´ ıa-Redondo et al. 2002 [19]
Italy 225 0 0 SSCP Batlistini et al. 2005 [20]
Spain (Catalonia) 94 4 4.2 D90A, N139H, A140A DS Gamez et al. 2006 [4]
Italy 66 3 4.5 K135X, N65S, A95T DHPLC Corrado et al. 2006 [5]
Italy 303 2 066 N19S, E133ΔED H P L C C h i ` o et al. 2008 [6]
Japan 184 3 1.6 C6Y, Q22H, S134T HRM This article group1
Japan 255 4 1.5 K3E, G93S HRM This article group2
Total 2119 51 2.4
DS: direct sequence (no screening method in the article).
countries (Table 2). The prevalence was high in the Scottish
population (7%) and widely ranged in Italy (0%–6%), but
in other countries, it was 2 to 4%, similar to our data. This
time we found four novel mutationsin SALScases, and these
mutations were not found in the Japanese control group.
In a sporadic ALS patient carrying an SOD1 mutation, it
is also diﬃcult to ascertain whether it is a genuine sporadic
case, a case due to a mutation, or a familial case with
incomplete penetrance. To date, an SALS case with H80A
is the only one with a proven de novo mutation [23].
In our analysis, the G93S mutation was found in three
unrelated patients from the Tokai district of Japan (personal
communication). There are at least 6 Japanese families with
G93S, 4 of the 6 families being reported to be residents of the
Tokaidistrict[24–26].TheaccumulationofG93SinJapanese
SALS cases suggests the possibility of decreased penetrance
or an incomplete family history rather than a de novo
mutation.
4.3. Clinical Characteristics of SALS Involving SOD1 Muta-
tions. Clinical characteristics such as onset age, onset symp-
toms, and clinical course of so far reported SALS patients
having SOD1 mutations are summarized in Table 3.S i n c e
A4V, D90A, and I113T have been observed worldwide and
are considered to be the most common mutations in both
familial and sporadic ALS cases [4, 7]. Because of the
diﬃculty to deﬁne true sporadic, we did not include these
three mutations in the table. Based on the results of analysis
of these 20 SOD1 mutations in 27 sporadic ALS patients
(13 men, 10 women, and 4 unknown), the average age at
onset was 43.8 (range 18–77) years, which is about 10 years
younger that the mean age at onset reported for the sporadic
ALSpopulation[22].Theonset symptom was limb weakness
in 21 cases and bulbar dysfunction only in one case. The
clinical courses were underthree years (rapid) in sevencases,
over six years (slow) in nine cases, and three to six years
(moderate) in ﬁve cases. The clinical characteristics of SALS
involving SOD1 mutations indicate a relatively young onset
age and a high percentage of limb involvement at onset.
These characteristics are similar to the features of ALSOD
(ALSpatientshavingSOD1mutations),notthoseofsporadic
ALS [29].
The C6Y mutation in our case was diﬃcult to diagnose
because the main symptom was lower motor neuron dys-
function and the onset age was young (midthirties). But
this clinical course was similar to that in the case of de
novo mutation H80A [23] .T h e r ew e r en i n e( b o l d )p a t i e n t s
whose onset ages were under forty, and eight of them had
rapid or moderate clinical course (Table 3). On the other
hand, there are four (underlined) patients whose onset ages
were over 55, and three of them had slow clinical course
(Table 3). Gamez and his colleagues reported [4] there were
three types of sporadic ALS patients who were particular
candidates for genetic testing for SOD1:( a )t h o s ew i t h
the typical Scandinavian phenotype, (b) those with clinical
onset before 55 years of age, and (c) patients with slow
progression/long survival. Compare with this theory (b)
and (c), only one patient (N19S) is an exception for SOD1
screening.
5.Conclusion
We have demonstrated that HRM analysis is a rapid and
sensitive method for the mutation scanning of SOD1.W i t h
this method, four novel SOD1 mutations were found in
SALS cases, the prevalence of SOD1 mutations in Japanese
SALS cases being 1.6%. The clinical characteristics of SALS
involving SOD1 mutations are a young onset age and a high
percentageoflimbinvolvementatonset.Wewill screenother
causativegenesforALS(TDP-43,ANG,FUS/TLS,OPTN and
others) by HRM analysis and determine the cause of disease
appearance.Neurology Research International 7
Table 3: Clinical characteristics of the SALS patients having SOD1 mutations.
Amino acid
change
Sequence
change No. of pt. Onset age Onset symptom
Disease
course/Disease
duration
Author/Reference
K3E AAG > GAG 1 52 Right leg weakness Moderate, 6y This article
C6Y TGC > TAC 1 34 Right leg weakness Moderate, 3y This article
V14G GTG > GGG 1 39 Both legs fatigue ND, 16m∼ Andersen et al. [16]
G16S GGC > AGC 1 18 Hand paresis Rapid, 1y Kawamata et al. [27]
N19S AAT > AGT 2 32
41
Both legs weakness
Left arm weakness
Moderate, 36m
ND
Mayeux et al. [28]
17 7 Hand paresis Rapid, 15m Chi` oe ta l .[ 6]
E21K GAG > AAG 1 ND ND ND Jones et al. [2]
Q22H CAG > CAC 1 46 Left leg weakness Slow, 8y This article
N65S AAT > AGT 1 44 Left leg weakness Slow, 14y
Garc´ ıa-Redondo et al.
[19]
1 40 Drop foot Slow, 11y Corrado et al. [5]
G72S GGT > AGT 1 29 Left leg weakness Rapid, 15m Shaw et al. [18]
H80A CAT > CGT 1 24 Left leg weakness Rapid, 18m Alexander et al. [23]
G93S GGT > AGT 3
44
55
64
Both legs weakness
Left leg weakness
Right leg weakness
ND, 6y∼
Slow, 8y∼
Slow, 12y∼
This article
A95T GCC > ACC 1 26 Both legs weakness Slow Gellera et al. [22]
1 45 Left drop foot Slow, 20y Corrado et al. [5]
D101N GAT > AAT 1 53 ND ND Jones et al. [14]
V118
KTGPX
GTG >
AAAACTG 1 34 ND Rapid, 16m Jackson et al. [17]
E133ΔE GAA del
GAA 1 54 Left leg weakness Moderate, 4y Chi` oe ta l .[ 6]
S134T AGT > ACT 1 62 Both legs weakness Slow, 7y This article
K136X AAG > TAG 1 45 Left leg weakness Rapid,12m Corrado et al. [5]
N139H AAG > CAC 1 53 ND ND Gamez et al. [4]
N139N AAC > AAT 1 33 ND Moderate, 3y
Aguirre et al. [3]
A140A GCT > GCA 2 52
ND
Bulbar palsy
Limb weakness
Rapid, 22m
Slow Gamez et al. [4]
Total/Average 20 27 43.8
21 Extremity 7 Rapid
1B u l b a r 5M o d e r a t e
5N od a t a 9S l o w
ND: no data, y: year or years, m: month or months, and y∼ or m∼: alive at the reported time.
Age: under forty (bold) and over ﬁfty-ﬁve (underlined).
Disease course (until invasive ventilation support): ∼2y e a r s ,r a p i d ;3 – 6y e a r s ,m o d e r a t e ;7 ∼ years, slow.
Acknowledgments
The authors are grateful to the Japanese Consortium for
Amyotrophic Lateral Sclerosis research (JaCALS) for provid-
ing the DNA samples. This work was supported by Grants-
in-Aid from the Research Committee of CNS Degenerative
Diseases, the Ministry of Health, Labour and Welfare of
Japan. This publication was subsidized by the JKA through
its promotion funds from KEIRIN RACE.
References
[1] L. P. Rowland and N. A. Shneider, “Amyotrophic lateral
sclerosis,” New England Journal of Medicine, vol. 344, no. 22,
pp. 1688–1700, 2001.
[2] C. T. Jones, R. J. Swingler, S. A. Simpson, and D. J. H. Brock,
“Superoxide dismutase mutations in an unselected cohort
of Scottish amyotrophic lateral sclerosis patients,” Journal of
Medical Genetics,vol. 32, no. 4, pp. 290–292, 1995.8 Neurology Research International
[3] T. Aguirre, G. Matthijs, W. Robberecht, P. Tilkin, and J.
J. Cassiman, “Mutational analysis of the Cu/Zn superoxide
dismutase gene in 23 familial and 69 sporadic cases of
amyotrophic lateral sclerosis in Belgium,” European Journal of
Human Genetics,vol. 7, no. 5, pp. 599–602, 1999.
[4] J. Gamez, M. Corbera-Bellalta, G. Nogales et al., “Mutational
analysis of the Cu/Zn superoxide dismutase gene in a Catalan
ALSpopulation:shouldallsporadicALScasesalsobescreened
for SOD1?”Journal of the Neurological Sciences,vol. 247,no. 1,
pp. 21–28, 2006.
[ 5 ]L .C o r r a d o ,S .D ’ A l f o n s o ,L .B e r g a m a s c h ie ta l . ,“ S O D 1g e n e
mutations in Italian patients with Sporadic Amyotrophic
Lateral Sclerosis (ALS),” Neuromuscular Disorders,v o l .1 6 ,n o .
11, pp. 800–804, 2006.
[6] A.Chi` o,B.J.Traynor,F.Lombardoetal.,“PrevalenceofSOD1
mutations in the Italian ALS population,” Neurology, vol. 70,
no. 7, pp. 533–537, 2008.
[7] P. M. Andersen, “Amyotrophic lateral sclerosis associated with
mutations in the CuZn superoxide dismutase gene,” Current
Neurology and Neuroscience Reports, vol. 6, no. 1, pp. 37–46,
2006.
[ 8 ]R .D e lB o ,S .G h e z z i ,S .C o r t ie ta l . ,“ T A R D B P( T D P - 4 3 )
sequence analysis in patients with familial and sporadic ALS:
identiﬁcation of two novel mutations,” European Journal of
Neurology, vol. 16, no. 6, pp. 727–732, 2009.
[9] H. Daoud, P. N.Valdmanis,E. Kabashiet al.,“Contribution of
TARDBP mutationsto sporadic amyotrophiclateral sclerosis,”
Journal of Medical Genetics,vol. 46, no. 2, pp. 112–114, 2009.
[10] A. Paubel, J. Violette, M. Amy et al., “Mutations of the ANG
gene in French patients with sporadic amyotrophic lateral
sclerosis,”Archives ofNeurology,vol.65,no.10,pp.1333–1336,
2008.
[11] T. J. Kwiatkowski,D. A. Bosco, A. L. LeClerc et al., “Mutations
in the FUS/TLS gene on chromosome 16 cause familial
amyotrophic lateral sclerosis,” Science, vol. 323, no. 5918, pp.
1205–1208, 2009.
[ 1 2 ]H .M a r u y a m a ,H .M o r i n o ,H .I t oe ta l . ,“ M u t a t i o n so f
optineurin in amyotrophic lateral sclerosis,” Nature, vol. 465,
no. 7295, pp. 223–226, 2010.
[13] C. T. Wittwer, G. H. Reed, C. N. Gundry, J. G. Vandersteen,
and R. J. Pryor, “High-resolution genotyping by amplicon
melting analysis using LCGreen,” Clinical Chemistry, vol. 49,
no. 6, pp. 853–860, 2003.
[14] C. T. Jones, P. J. Shaw, G. Chari, and D. J. H. Brock,
“Identiﬁcation of a novel exon 4 SOD1 mutationin a sporadic
amyotrophic lateral sclerosis patient,” Molecular and Cellular
Probes, vol. 8, no. 4, pp. 329–330, 1994.
[15] C. T. Jones, R. J. Swingler, and D. J. H. Brock, “Identiﬁca-
tion of a novel SOD1 mutation in an apparently sporadic
amyotrophic lateral sclerosis patient and the detection of
Ile113Thr in three others,” Human Molecular Genetics,v o l .3 ,
no. 4, pp. 649–650, 1994.
[16] P. M. Andersen, P. Nilsson, M. L. Ker¨ anen et al., “Phenotypic
heterogeneity in motor neuron disease patients with CuZn-
superoxide dismutase mutations in Scandinavia,” Brain,v o l .
120, no. 10, pp. 1723–1737, 1997.
[17] M.J ac kson,A .A l- C halab i,Z.E .E na y at ,B .C hioza,P .N .L e igh,
and K. E. Morrison,“Copper/zinc superoxide dismutase1 and
sporadic amyotrophic lateral sclerosis: analysis of 155 cases
and identiﬁcation of a novel insertion mutation,” Annals of
Neurology, vol. 42, no. 5, pp. 803–807, 1997.
[18] C. E. Shaw, Z. E. Enayat, B. A. Chioza et al., “Mutations in all
ﬁve exons of SOD-1 may cause ALS,” Annals of Neurology,v o l .
43, no. 3, pp. 390–394, 1998.
[19] A. Garc´ ıa-Redondo, F.Bustos,B.JuanYSevaetal.,“Molecular
analysisofthesuperoxidedismutase1geneinSpanishpatients
withsporadicorfamilialamyotrophiclateralsclerosis,”Muscle
and Nerve, vol. 26, no. 2, pp. 274–278, 2002.
[20] S. Battistini, F. Giannini, G. Greco et al., “SOD1 mutations in
amyotrophiclateralsclerosis:results fromamulticenterItalian
study,” Journal of Neurology, vol.252,no.7,pp. 782–788,2005.
[ 2 1 ]R .G .M i l l e r ,T .L .M u n s a t ,M .S w a s h ,a n dB .R .B r o o k s ,
“Consensus guidelines for the design and implementation
of clinical trials in ALS. World Federation of Neurology
committee on Research,” Journal of the Neurological Sciences,
vol. 169, no. 1-2, pp. 2–12, 1999.
[22] C. Gellera, B. Castellotti, M. C. Riggio et al., “Superoxide
dismutase gene mutations in Italian patients with familial and
sporadic amyotrophic lateral sclerosis: identiﬁcation of three
novel missense mutations,” Neuromuscular Disorders,v o l .1 1 ,
no. 4, pp. 404–410, 2001.
[23] M. D. Alexander, B. J. Traynor, N. Miller et al., ““True”
sporadic ALS associated with a novel SOD-1 mutation,”
Annals of Neurology, vol. 52, no. 5, pp. 680–683, 2002.
[24] K. Iwai,M. Yamamoto,T. Yoshihara,and G. Sobue, “Anticipa-
tion in familialamyotrophic lateral sclerosis with SOD1-G93S
mutation,” Journal of Neurology Neurosurgery and Psychiatry,
vol. 72, no. 6, pp. 819–820, 2002.
[ 2 5 ]A .K a w a t a ,S .K a t o ,H .H a y a s h i ,a n dS .H i r a i ,“ P r o m i n e n t
sensory and autonomic disturbances in familial amyotrophic
lateral sclerosis with a Gly93Ser mutation in the SOD1 gene,”
Journal of the Neurological Sciences, vol. 153, no. 1, pp. 82–85,
1997.
[26] M. Suzuki, T. Irie, T. Watanabe et al., “Familial amyotrophic
lateral sclerosis with Gly93Ser mutation in Cu/Zn superoxide
dismutase: a clinical and neuropathological study,” Journal of
the Neurological Sciences, vol. 268, no. 1-2, pp. 140–144, 2008.
[ 2 7 ]J .K a w a m a t a ,S .S h i m o h a m a ,S .T a k a n o ,K .H a r a d a ,K .U e d a ,
and J. Kimura, “Novel G16S (GGC-AGC) mutation in the
SOD-1geneinapatientwithapparently sporadicyoung-onset
amyotrophic lateral sclerosis,” Human Mutation,v o l .9 ,n o .4 ,
pp. 356–358, 1997.
[ 2 8 ]V .M a y e u x ,P .C o r c i a ,G .B e s s o n ,H .F .J a f a r i - S c h l u e p ,V .
B r i o l o t t i ,a n dW .C a m u ,“ N 1 9 S ,an e wS O D 1m u t a t i o ni n
sporadic amyotrophic lateral sclerosis: no evidence for disease
causation,” Annals of Neurology, vol. 53, no. 6, pp. 815–818,
2003.
[ 2 9 ]M .E .C u d k o w i c z ,D .M c K e n n a - Y a s e k ,P .E .S a p pe ta l . ,
“Epidemiology of mutations in superoxide dismutase in
amyotrophiclateralsclerosis,”Annals of Neurology, vol.41,no.
2, pp. 210–221, 1997.